Neurosense Therapeutics Ltd C/W (NASDAQ:NRSNW)
| Market Cap | 989.13K-93.0% |
| Revenue (ttm) | 0 |
| Net Income | -11.13M-9.0% |
| EPS | -0.45+24.6% |
| Shares Out | 24.67M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,107 |
| Open | 0.30 |
| Previous Close | 0.08 |
| Day's Range | 0.04 - 0.30 |
| 52-Week Range | 0.04 - 0.60 |
| Beta | 1.60 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Dec 2, 2026 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About NRSNW
NeuroSense Therapeutics Ltd. is an Israeli clinical-stage biotechnology firm dedicated to pioneering novel therapies for severe neurodegenerative conditions. Its most advanced investigational asset is PrimeC, an innovative oral compound specifically engineered to address amyotrophic lateral sclerosis (ALS). Beyond its lead program, the company boasts a preclinical pipeline featuring StabiliC, aimed at Parkinson's disease, and CogniC, targeting Alzheimer's disease. Established in Herzliya, Israel, in 2017, NeuroSense Therapeutics continues to advance its therapeutic initiatives.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$NRSNW stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in NRSNW holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by NRSNW's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
NRSNW Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New NRSNW patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to NRSNW from public contracts
Source: USAspending.gov
NRSNW Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from NRSNW’s recent data — informational, not investment advice